AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35714812
Drug: GSK3389404 (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3389404 (120 mg weekly)
Trial: 35714812
Drug: GSK3389404 (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3389404 (120 mg bi-weekly)
Trial: 35714812
Drug: GSK3389404 (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3389404 (120 mg weekly, 120 mg bi-weekly)
Trial: 32932891
Drug: Ultrasound-guided injection
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided injection of Botulinum Toxin Type A (24 U)
Trial: 32932891
Drug: Conventional blind
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional blind injection of Botulinum Toxin Type A (24 U)
Trial: 34209804
Drug: Lacticaseibacillus paracasei
RxNorm normalized name: Lacticaseibacillus paracasei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacticaseibacillus paracasei strain Shirota (LcS) beverage (100 mL, 108 CFU/mL)
Trial: 38263652
Drug: Subcutaneous iscalimab
RxNorm normalized name: Iscalimab
DrugBank: Iscalimab (DB15260)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous iscalimab (3 mg/kg)
Trial: 35952529
Drug: Dexamethasone IV
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone IV combined with 15 sessions of hyperbaric oxygen therapy (SS + HBOT)
Trial: 33893799
Drug: BCG vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccination + oral polio vaccine (OPV) immediately upon admission
Trial: 34973048
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (PE and AR)
Trial: 34632490
Drug: Furosemide 80
RxNorm normalized name: furosemide 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 80 mg bolus
Trial: 34049356
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no immunotherapy)
Trial: 39392168
Drug: Intravenous tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tenecteplase
Trial: 32175662
Drug: Nicorandil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (2 mg injected into the coronary artery)
Trial: 33952670
Drug: ticagrelor (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily on days 2‐90) plus open-label aspirin (75-300 mg on day 1 followed by 75 mg daily on days 2-21)
Trial: 33952670
Drug: clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clopidogrel (300 mg loading dose on day 1 followed by 75 mg daily on days 2‐90) plus open-label aspirin (75-300 mg on day 1 followed by 75 mg daily on days 2-21)
Trial: 37980467
Drug: RTS,S/AS01 malaria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01 malaria vaccine
Trial: 36224244
Drug: Active M1‐rTMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active M1‐rTMS (10 Hz for 10 daily treatments over 2 weeks)
Trial: 33147621
Drug: Dopaminergic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopaminergic medication (200/50 mg levodopa-benserazide)
Trial: 33147621
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (OFF medication)
Trial: 36461704
Drug: 6 mm
RxNorm normalized name: I-Port, 6 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mm short implants
Trial: 36461704
Drug: 11 mm
RxNorm normalized name: Interleukin 11
DrugBank: Oprelvekin (DB00038)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 11 mm long implants
Trial: 32128718
Drug: After twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After twice artificial abortion (ATAA)
Trial: 33298154
Drug: Duloxetine, antivirals,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine, antivirals, and analgesics
Trial: 33298154
Drug: Control (antivirals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (antivirals and analgesics only)
Trial: 34344428
Drug: Culture‐directed antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culture‐directed antibacterial therapy based on percutaneous bone biopsy culture results
Trial: 34344428
Drug: Culture‐directed antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culture‐directed antibacterial therapy based on ulcer bed biopsy culture results
Trial: 33860324
Drug: SNP selection
RxNorm normalized name: SNP-ACTH (1-39)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNP selection strategy using a combination of mean minor allele frequency (MAF) and linkage disequilibrium (LD)
Trial: 35491532
Drug: Canagliflozin 100
RxNorm normalized name: canagliflozin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 100 mg daily
Trial: 33243277
Drug: Double Sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double Sequential External Defibrillation (DSED)
Trial: 33704698
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of exercise training
Trial: 33704698
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of exercise training
Trial: 33020354
Drug: S One
RxNorm normalized name: Nestabs ONE
DrugBank: Calcium ascorbate (DB14483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S One Group II (used instruments after ex vivo treatment)
Trial: 36074963
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 24% Su and LC 30 minutes before puncture
Trial: 32403367
Drug: Glucose-based TPN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-based TPN (group G)
Trial: 32403367
Drug: Lipid-based TPN
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based TPN (group L)
Trial: 32248227
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (NMES, TENS, NMES/TENS)
Trial: 32697484
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human soluble thrombomodulin (0.06 mg/kg/d; n = 395)
Trial: 34351368
Drug: Less-intensive therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less-intensive therapies
Trial: 34351368
Drug: Intensive therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapies
Trial: 32180692
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving an alternative meal (e.g. chicken, pork, and beef)
Trial: 33349280
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for insomnia (CBT-I); 8 sessions
Trial: 33730722
Drug: Ginseng (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginseng (twice daily for 4 weeks)
Trial: 35726506
Drug: Oral Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Isotretinoin
Trial: 33310418
Drug: eculizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eculizumab (1200 mg/2 weeks)
Trial: 32460799
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (self-administered test of alcohol use and advice regarding usual treatment in Estonia)
Trial: 34424995
Drug: Colloid-based priming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloid-based priming solution (dextran 40)
Trial: 34424995
Drug: Crystalloid-based priming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid-based priming solution (Ringer-Acetate plus mannitol)
Trial: 33854007
Drug: UIC201609/UIC201610 (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UIC201609/UIC201610 (combination of rabeprazole and CR mosapride)
Trial: 33854007
Drug: rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 10 mg once a day
Trial: 33854007
Drug: mosapride 15
RxNorm normalized name: mosapride
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mosapride 15 mg CR tablet once a day
Trial: 34928306
Drug: Erenumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab (both doses)
Trial: 33463426
Drug: Epinephrine (EPN)
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine (EPN) irrigation solution (0.33 mg per 1 L of saline)
Trial: 33463426
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) irrigation solution (0.42 mg per 1 L of saline)
Trial: 33153578
Drug: LDL-C <70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C <70 mg/dl
Trial: 34903035
Drug: Renal denervation
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal denervation (RDN) therapy
Trial: 32191001
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium suppositories
Trial: 35255859
Drug: Sexual and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sexual and Reproductive Health (SRH): Baseline self-collected vaginal and urine samples with study-organized clinic appointments for results, treatment and delivery of HIV testing, ART and PrEP integrated with SRH services
Trial: 35255859
Drug: SRH +
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRH + peer-support: Combination of SRH services and peer navigator support
Trial: 36031597
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light therapy
Trial: 35491787
Drug: Sham light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham light therapy
Trial: 35999562
Drug: Berberine and
RxNorm normalized name: berberine
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine and fenugreek co-supplementation (3 capsules/day of 500 mg: 300 mg of berberine + 200 mg of fenugreek seed powder) for 12 weeks
Trial: 34712203
Drug: Decaffeinated green
RxNorm normalized name: (-)-EPIGALLOCATECHIN-3-O-GALLATE (EGCG) (CONSTITUENT OF POWDERED DECAFFEINATED GREEN TEA EXTRACT) [DSC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated green tea polyphenols (DGTP) 400 mg/day for 12 weeks
Trial: 33553662
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention by clinical pharmacists including training on IBS-related knowledge, medication adherence, lifestyle, and diet adjustments.
Trial: 33553662
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy (nonintervention group).
Trial: 33037036
Drug: Exenatide two
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide two times per day (5 mcg for 4 weeks, followed by 10 mcg for 28 weeks)
Trial: 33037036
Drug: Exenatide QWS-AI
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide QWS-AI (2 mg) continued for 52 weeks
Trial: 35143603
Drug: Intra-arterial alteplase
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial alteplase (0.225 mg/kg; maximum dose, 22.5 mg) infused over 15 to 30 minutes
Trial: 33606922
Drug: GSK3352589 single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3352589 single-dose (2 to 400 mg, including 25 mg food effect arm)
Trial: 33606922
Drug: GSK3352589 repeat-dose
RxNorm normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3352589 repeat-dose (5 to 200 mg, twice daily for 14 days with food)
Trial: 33606922
Drug: GSK3352589 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3352589 (both single and repeat doses)
Trial: 32297043
Drug: Urea at
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea at 40 g/kg DM
Trial: 32297043
Drug: Urea at
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea at 60 g/kg DM
Trial: 32297043
Drug: NaOH at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaOH at 40 g/kg DM
Trial: 32297043
Drug: NaOH at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaOH at 60 g/kg DM
Trial: 32297043
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no chemical treatment)
Trial: 35802515
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise therapy for 3 months
Trial: 35802515
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise therapy for 3 months (adherent participants)
Trial: 34931603
Drug: Positive airway
RxNorm normalized name: VersaPAP Positive Airway Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive airway pressure (PAP) treatment
Trial: 33461636
Drug: Asenapine 10
RxNorm normalized name: asenapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine 10 mg/day
Trial: 33461636
Drug: Asenapine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine 20 mg/day
Trial: 34080890
Drug: Varenicline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline plus Naltrexone (2 mg/day of varenicline plus 50 mg/day of naltrexone)
Trial: 34080890
Drug: Varenicline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline plus Placebo (2 mg/day of varenicline plus matched placebo)
Trial: 32783585
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of lidocaine/prilocaine (EMLA)
Trial: 32783585
Drug: Patch electrode
RxNorm normalized name: ELECTRODE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch electrode stimulation
Trial: 35908601
Drug: Active capacitive-resistive
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active capacitive-resistive electrical therapy to the lower cervical region (C4-C7), twice weekly for a total of six treatments
Trial: 35908601
Drug: Sham (inactive)
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham (inactive) treatment
Trial: 32389738
Drug: Topical tacalcitol
RxNorm normalized name: tacalcitol Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacalcitol plus 5‐aminolevulinic acid photodynamic therapy (ALA‐PDT)
Trial: 32389738
Drug: 5‐aminolevulinic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐aminolevulinic acid photodynamic therapy (ALA‐PDT) alone
Trial: 33798311
Drug: Cupping treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cupping treatment combined with antibiotics (cefodizine sodium 80 mg/(kg•d) for 7 days)
Trial: 33798311
Drug: Antibiotics alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics alone (cefodizine sodium 80 mg/(kg•d) for 7 days)
Trial: 35248132
Drug: Low-dose ticagrelor
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ticagrelor combined with 100 mg aspirin
Trial: 35248132
Drug: Standard-dose ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose ticagrelor combined with 100 mg aspirin
Trial: 32194222
Drug: Placebo (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (900 mg of edible paraffin)
Trial: 35686998
Drug: Daily cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily cannabis use after acute cannabis use
Trial: 32560639
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab 0.5 mg alone
Trial: 32560639
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab 0.5 mg with macular laser
Trial: 32955601
Drug: Erector spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector spinae plane (ESP) block with 20 ml of 0.25% bupivacaine
Trial: 32955601
Drug: Mid-transverse to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-transverse to pleura (MTP) block with 20 ml of 0.25% bupivacaine
Trial: 34118712
Drug: StaySafe app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: StaySafe app (12 weekly sessions)
Trial: 32654362
Drug: Standard sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sequential treatment of sunitinib followed by everolimus
Trial: 36419181
Drug: IV ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketamine (KET) 0.5 mg/kg over 40 min
Trial: 36419181
Drug: IM naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM naltrexone (NTX) 380 mg once
Trial: 33205924
Drug: FDS76® dental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDS76® dental implant
Trial: 32924897
Drug: Bright white
RxNorm normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright white light therapy (BLT)
Trial: 33549453
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving a monthly motivational phone call
Trial: 37355526
Drug: Neoadjuvant systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant systemic therapy (NST)
Trial: 35799113
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of medications
Trial: 35395069
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg daily (females subgroup)
Trial: 35395069
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg daily (males subgroup)
Trial: 35644071
Drug: Flumazenil (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (4 mg/24 h for approximately eight days)
Trial: 34116204
Drug: EPCO patients
RxNorm normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPCO patients with different treatment durations
Trial: 33768537
Drug: Waitlist control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist control (treatment as usual).
Trial: 32419281
Drug: Isoflavones (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavones (100 mg daily for 8 weeks)
Trial: 32758312
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure therapy (PE-A)
Trial: 33394814
Drug: Self-reported drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported drug use by questionnaires
Trial: 33976537
Drug: High-dose lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose lidocaine (Group HL: 1.5 mg/kg bolus followed by an infusion at 2.0 mg/kg/hour)
Trial: 33976537
Drug: Low-dose lidocaine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose lidocaine (Group LL: 1.5 mg/kg bolus followed by an infusion at 1.0 mg/kg/hour)
Trial: 33976537
Drug: High-dose lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose lidocaine (Group HL)
Trial: 35982198
Drug: Lidocaine administration
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine administration
Trial: 34260478
Drug: Low-fat, vegan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat, vegan diet including ½ cup (86 g) of cooked soybeans daily for 12 weeks
Trial: 32077907
Drug: Nonstudy eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonstudy eye received DME treatment within 4 months of randomization
Trial: 35794673
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen 1 g 4 times a day
Trial: 32402480
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg i.v. haloperidol
Trial: 33395437
Drug: COTiD-UK (Community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COTiD-UK (Community Occupational Therapy for people with dementia)